Guangzhou Bibet Pharmaceutical Technology

Bibet Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the discovery and development of innovative small molecule drugs for oncology and metabolic diseases. The company leverages its proprietary dual-target drug design platform to develop therapies that address complex disease mechanisms more effectively than single-target agents. Its lead candidate, BEBT-908, is a dual PI3K/HDAC inhibitor currently in pivotal clinical trials for the treatment of relapsed or refractory lymphomas. Beyond oncology, Bibet is advancing a diverse pipeline of candidates targeting CDK4/6, EGFR, and URAT1, aiming to provide high-quality, affordable innovative medicines to patients globally.